Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer

Research output: Contribution to journalArticle

Abstract

Purpose: Comorbidity with hypertension (HTN) may affect the outcome of castration-resistant prostate cancer (CRPC). In this study, we evaluated the prognostic impact of antihypertensive agents in patients with CRPC treated with androgen receptor axis-targeting (ARAT) agents or docetaxel chemotherapy. Patients and methods: This study included 156 Japanese men with CRPC who were treated with ARAT agents (n = 85) or docetaxel (n = 71) at our hospital between 2008 and 2017. Associations between clinicopathological factors, HTN status, progression-free survival (PFS) and overall survival (OS) were evaluated by univariate and multivariate analysis. Results: When adjusted for age, prostate-specific antigen levels at pretreatment, Gleason score, and clinical M-stage, comorbid HTN was significantly associated with better OS (hazards ratio, 95% confidence interval: 0.41, 0.21–0.77; P = 0.0051), but not with PFS (hazards ratio, 95% confidence interval: 0.64, 0.38–1.11; P = 0.11) in patients treated with ARAT agent. However, HTN was not associated with PFS or OS for patients treated with docetaxel. Conclusions: Use of antihypertensive agents has prognostic significance for patients with CRPC treated with ARAT agent, but not docetaxel.

Original languageEnglish
Pages (from-to)813.e21-813.e26
JournalUrologic Oncology: Seminars and Original Investigations
Volume37
Issue number11
DOIs
Publication statusPublished - Nov 2019

Fingerprint

docetaxel
Castration
Antihypertensive Agents
Androgen Receptors
Prostatic Neoplasms
Disease-Free Survival
Hypertension
Survival
Confidence Intervals
Neoplasm Grading
Prostate-Specific Antigen
Comorbidity
Multivariate Analysis
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

@article{f3099275c92a473a97802278131eb891,
title = "Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer",
abstract = "Purpose: Comorbidity with hypertension (HTN) may affect the outcome of castration-resistant prostate cancer (CRPC). In this study, we evaluated the prognostic impact of antihypertensive agents in patients with CRPC treated with androgen receptor axis-targeting (ARAT) agents or docetaxel chemotherapy. Patients and methods: This study included 156 Japanese men with CRPC who were treated with ARAT agents (n = 85) or docetaxel (n = 71) at our hospital between 2008 and 2017. Associations between clinicopathological factors, HTN status, progression-free survival (PFS) and overall survival (OS) were evaluated by univariate and multivariate analysis. Results: When adjusted for age, prostate-specific antigen levels at pretreatment, Gleason score, and clinical M-stage, comorbid HTN was significantly associated with better OS (hazards ratio, 95{\%} confidence interval: 0.41, 0.21–0.77; P = 0.0051), but not with PFS (hazards ratio, 95{\%} confidence interval: 0.64, 0.38–1.11; P = 0.11) in patients treated with ARAT agent. However, HTN was not associated with PFS or OS for patients treated with docetaxel. Conclusions: Use of antihypertensive agents has prognostic significance for patients with CRPC treated with ARAT agent, but not docetaxel.",
author = "Masaki Shiota and Takeshi Kobayashi and Eiji Kashiwagi and Ario Takeuchi and Junichi Inokuchi and Katsunori Tatsugami and Masatoshi Eto",
year = "2019",
month = "11",
doi = "10.1016/j.urolonc.2019.04.020",
language = "English",
volume = "37",
pages = "813.e21--813.e26",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer

AU - Shiota, Masaki

AU - Kobayashi, Takeshi

AU - Kashiwagi, Eiji

AU - Takeuchi, Ario

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Eto, Masatoshi

PY - 2019/11

Y1 - 2019/11

N2 - Purpose: Comorbidity with hypertension (HTN) may affect the outcome of castration-resistant prostate cancer (CRPC). In this study, we evaluated the prognostic impact of antihypertensive agents in patients with CRPC treated with androgen receptor axis-targeting (ARAT) agents or docetaxel chemotherapy. Patients and methods: This study included 156 Japanese men with CRPC who were treated with ARAT agents (n = 85) or docetaxel (n = 71) at our hospital between 2008 and 2017. Associations between clinicopathological factors, HTN status, progression-free survival (PFS) and overall survival (OS) were evaluated by univariate and multivariate analysis. Results: When adjusted for age, prostate-specific antigen levels at pretreatment, Gleason score, and clinical M-stage, comorbid HTN was significantly associated with better OS (hazards ratio, 95% confidence interval: 0.41, 0.21–0.77; P = 0.0051), but not with PFS (hazards ratio, 95% confidence interval: 0.64, 0.38–1.11; P = 0.11) in patients treated with ARAT agent. However, HTN was not associated with PFS or OS for patients treated with docetaxel. Conclusions: Use of antihypertensive agents has prognostic significance for patients with CRPC treated with ARAT agent, but not docetaxel.

AB - Purpose: Comorbidity with hypertension (HTN) may affect the outcome of castration-resistant prostate cancer (CRPC). In this study, we evaluated the prognostic impact of antihypertensive agents in patients with CRPC treated with androgen receptor axis-targeting (ARAT) agents or docetaxel chemotherapy. Patients and methods: This study included 156 Japanese men with CRPC who were treated with ARAT agents (n = 85) or docetaxel (n = 71) at our hospital between 2008 and 2017. Associations between clinicopathological factors, HTN status, progression-free survival (PFS) and overall survival (OS) were evaluated by univariate and multivariate analysis. Results: When adjusted for age, prostate-specific antigen levels at pretreatment, Gleason score, and clinical M-stage, comorbid HTN was significantly associated with better OS (hazards ratio, 95% confidence interval: 0.41, 0.21–0.77; P = 0.0051), but not with PFS (hazards ratio, 95% confidence interval: 0.64, 0.38–1.11; P = 0.11) in patients treated with ARAT agent. However, HTN was not associated with PFS or OS for patients treated with docetaxel. Conclusions: Use of antihypertensive agents has prognostic significance for patients with CRPC treated with ARAT agent, but not docetaxel.

UR - http://www.scopus.com/inward/record.url?scp=85067031558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067031558&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2019.04.020

DO - 10.1016/j.urolonc.2019.04.020

M3 - Article

AN - SCOPUS:85067031558

VL - 37

SP - 813.e21-813.e26

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 11

ER -